Liraglutide vs Glimepiride for Type 2 Diabetes
Author Information
Author(s): Alan Garber, Henry R R, Ratner R, Hale P, Chang C T, Bode B
Primary Institution: Baylor College of Medicine
Hypothesis
Liraglutide monotherapy is more effective than glimepiride monotherapy in improving glycaemic control and weight in patients with type 2 diabetes over 2 years.
Conclusion
Liraglutide monotherapy for 2 years provides significant and sustained improvements in glycaemic control and body weight compared with glimepiride monotherapy, at a lower risk of hypoglycaemia.
Supporting Evidence
- Liraglutide reduced HbA1c by −0.9% compared to −0.6% with glimepiride in the completer population.
- Liraglutide was associated with lower rates of minor hypoglycaemia compared to glimepiride.
- Participants on liraglutide experienced sustained weight loss over 2 years.
Takeaway
This study shows that taking liraglutide helps people with diabetes control their blood sugar and lose weight better than another medicine called glimepiride.
Methodology
Participants were randomized to receive liraglutide 1.2 mg, liraglutide 1.8 mg, or glimepiride 8 mg for 2 years, with evaluations of safety and efficacy.
Potential Biases
Potential investigator and participant bias due to the open-label design.
Limitations
The open-label nature of the extension may introduce bias, and there was a 57% withdrawal rate over 2 years.
Participant Demographics
Participants were aged 18-80 years with type 2 diabetes and a BMI ≤45 kg/m2.
Statistical Information
P-Value
p = 0.0376 for liraglutide 1.2 mg vs glimepiride; p = 0.0016 for liraglutide 1.8 mg vs glimepiride
Confidence Interval
95% CI: −0.71 to −0.02 for liraglutide 1.2 mg; 95% CI: −0.88 to −0.21 for liraglutide 1.8 mg
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website